Acellular Pertussis Completed Phase 2 Trials for Clostridium tetani toxoid antigen (formaldehyde inactivated) (DB10583)

IndicationStatusPhase
DBCOND0031302 (Acellular Pertussis)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01453998Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)Prevention
NCT01171989Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster DosePrevention
NCT00970307Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of AgePrevention
NCT01090453Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy InfantsPrevention
NCT01248884Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)Prevention
NCT00627458Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio's DTPa-HBV-IPV/Hib VaccinePrevention
NCT00376779Immunogenicity and Safety of a DTPa-HBV-IPV/Hib Vaccine Given at 2, 3 and 4 Months of AgePrevention